Aruvant’s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD).
Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.
Company Details
- Employees
- 7
- Address
- 151 W 42nd St, New York,ny 10036,united States
- IN****@****ANT.COM
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aruvant.com
- Keywords
- Rare Diseases.
- HQ
- New York, NY
Aruvant Questions
Aruvant's website is aruvant.com
Aruvant's LinkedIn profile is https://www.linkedin.com/company/aruvantsciences
Aruvant has
7 employees.
View email and phone details for 7
employees at Aruvant.
Aruvant's industry is
Biotechnology Research
Aruvant's top competitors are
Immunovant,
Priovant Therapeutics,
Jaguar Gene Therapy,
Sarepta Therapeutics,
Korro Bio, Inc.,
Hemavant Sciences,
Roivant,
Pulmovant,
Kinevant Sciences,
Sumitomo Pharma America, Inc..
Aruvant's support email address is INFO@ARUVANT.COM
Aruvant's categories are Biotechnology Research
